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 Apoptosis, or programmed cell death, is a common property of all multicellular 
organism. Apoptosis occurs normally during development and aging and as a homeostatic 
mechanism to maintain cell populations in tissue. Apoptosis also accurs as a defense 
mechanism such as in immune reactions or when cells are damaged by disease or noxious 
agents. Dysregulation of apoptosis leads to a variety of human pathologies including cancer, 




Exposure to various chemical 
agents can result in cell damage or death. 
Whether a cell survives or dies the 
presence of a chemical insults is often 
determined  by proliverative status, repair 
enzime capacity, and the ability to induce 
proteins that either promote or inhibit the 
cell death process. Much of our 
understanding about cell death and  its 
involvement in disease relates to its role in 
regulating tissue turnover or homeostasis. 
Tissue homeostasis occurs when a 
balance is achieved between cell renewal 
and cell death so that no net change in cell 
number is present.     Normal homeostatic 





Apoptosis, a biochemically and 
morphologically distinct forn of cell death, 
is an active process associated with cell 
shrinkage, nuclear and cytoplasmic 
condensation, release of cytochrome c 
from mitochondria, caspase activation, 
plasma membrane blebbing, 
phosphatidylserine extemalization on the 
plasma membrane, DNA fragmentation, 
and the formation of apoptotic bodies that 
can be taken up and degraded by 
neigh                            
                                           
                                 
                                         
                                         
                                            
 
p53 is a master regulator 
The ability of p53 to control 
passage through the cell cycle (in G1 and 
in G2) and to control apoptosis in 
response to abnormal proliverative signals 
and stress including DNA damage is 
considered to be important for its tumor 
suppression function (1). 
p53 is a transcription factor that 
establishes programmes for apoptosis, 
senescence, and repair in response to a 
variety of cellular stresses, including DNA 
damage, hypoxia or oncogenic avtivation, 
and nutrient deprivation, that contribute to 
tumor suppression either by preventing or 
repairing genomic damage or through the 
elimination of potentially oncogenic cells 
from the proliferating population. Known 
transcriptional targets  for p53 in 
promoting apoptosis include various pro-
apoptotic Bcl2 members, including puma, 
noxa, bid, and bax, as well as component 
of death-receptor signalling (for example, 
DR5, Fas/CD95), the apoptotic-effector 
machinery (for example, caspase-6, Apaf-
1, PIDD) and others with less well-defined 
roles (for example, PERP, PML, p53AIP). 
Additionally, p53 might directly facilitate 
cytochrome c release (6), (2). 
p53 protein becomes stabilized 
upon its phosporilation by ATM/Chk2 or 
ATR/Chk1/Casein-kinase 1 and 
accumulates in the nucleus. There, p53 
transcribes a network of genes that initiate 
DNA repair, growth arrest, senescence, 
and/or transcribing its negative regulator, 
the E3 ligase, Mdm2 which ubiquitinates 
p53 and targets it to the proteasome for 
degradation (12). 
Two main forms of cellular stress 
lead to activation of p53 for it to function 
as a transcriptional  activator. The first of 
these, and probably the best studied, is 
the one initiated by DNA damage which 
may be caused either by ionizing radiation 
or by chemotherapeutic drugs, ultraviolet 
light or protein kinase inhibitor. There are 
slight differences in which pathway is 
activated dependent on the mechanism of 
DNA damage but, in general, the check 
point proteins which signal to p53 that 
damage has occured and that cell cycling 
should be halted until DNA is repaired, are 
kinase. These include ATM (ataxia 
telangiectasia mutated), ChK1 and 2, 
DNA-PK (DNA-dependent protein kinase), 
JNK (JUN N-terminal kinase) and casein 
kinase 1 and 2. These kinase all 
phosphorylate p53 at amino terminal sites 
in the Mdm2-binding region of the protein, 
the effect being to block the interaction of 
Mdm2 and p53 allowing p53 stabilization. 
Mutations in ATM are associated  with the 
inherited condition, ataxia telangiectasia, 
and mutation in CHK2 have been found in 
a few families  with Fi-Fraumeni. Mutations 
in these genes therefore mean that they 
are no longer able to activate the p53 
pathway to allow repair to DNA damage 
which consequently leads to the 
development of cancers (8). 
The second pathway for activation 
of p53 occurs in the absence of DNA 
damage and results from deregulated 
oncogen expression. This provides a file-
safe mechanism to eliminate cell with 
proliverative abnormalities. The oncogene 
protein, e.g. RAS or MYC stimulate 
expression of the ARF gene, the protein 
product of which interacts with Mdm2 and 
inhibits its activity, again allowing levels of 
p53 to increase. The ARF protein also 
sequesters Mdm2 into the nucleolus so 
that it cannot interact with p53 in 
thenucleus (8).  
In light of the fundamental restraint  
yielded by p53, it not surprising then, that 
it is commonly inactivated in human 
cancer. Approximately 50% of sporadic 
human cancers cases, the integrity of the 
p53 signalling pathways is compromised 
indirect by various  mechanisms, such as 
upregulation of key negative regulation of 
p53. Mdm2 or Mdm4 (Mdmx). Likewise 
downregulation of the p53 activator. ARF 
leads to mouse tumorigenesis, reminiscent 
of p53 deficiency. In Li-Fraumeni 
syndrome patients, germline mutations in 
p53 results in early onset of multiple 
cancer types. A knockin of these mutation 
in mouse models further confirms the 
oncogenic ability of mutant p53 (8). 
Although p53 mutations are fairly 
ubiquitous and can be found in more than 
50% of human tumors, it is now well 
known that most types of cancer harbor 
specific genetic defects such as mutations 
in APC in colon cancer, BRCA1 and 
BRCA2 in breast cancer, and B-RAF in 
melanoma. As the p53 network is closely 
linked to many other cellular pathways, it 
is likely that defects in any of these 
pathway, either inherited or acquired 
somatically, could influence p53 function 
qualitatively or quantitatively (8). Another 
example is the relationship betwewn the 
BRCA1 and p53 pathways. BRCA1 acts 
both as a checkpoint and a DNA damage 
repair gene that ensures genome  
integrity. BRCA1 germ-line mutation are 
associated with an increased risk of 
developing breast and ovarian carcinoma 
(14). 
 
Molecular basis of apoptosis pathway 
The mechanisms of apoptosis are 
highly complex and sophisticated, 
involving an energy-dependent cascade of 
molecular events. To date, research 
indicates that there are two main apoptotic 
pathways; the extrinsic or death receptor 
pathway and  the intrinsic or mitochondrial 
pathway. However, there is now evidence 
that the two pathways are linked and that 
molecules  in one pathway can influence 
the other (4). 
Both of these pathways lead to 
caspase activation and cleavage of 
spesific cellular substrates. The receptors, 
such as Fas, TNF, TRAIL, and 
downstream molecules (i.e., caspases and 
Bcl-2 family members). The mitochondria-
apoptosome-mediated pathway includes 
the apoptotic stimuli induced by radiation 
therapy and chemotherapy, mitochondria, 
apoptosome, and key effector caspase. 
Caspase are activated in a cascade-like 
fashion. Initiator or upstream caspases 
(caspase 8, 9, 10) can activate affector or 
downstream caspases, including caspase 
3, 6, and 7, with leads to induction of 
apoptosis (13). 
Intrinsic pathway 
The intrinsic pathway is activated by 
various stimuli, such as DNA damage and 
cytotoxic insult, and acts through the 
mitochondria, which are controlled by the 
Bcl-2 family of proteins. In homeostatic 
conditions, the anti-apoptotic Bcl-2 family 
members maintain mitochondrial integrity 
by preventing the pro-apoptotic 
multidominan Bcl-2 family members Bax 
and Bak from causing mitochondrial 
damage. During cellular stress, Bcl-2-
homology 3 (BH3)-only proteins are 
activated and antagonize the anti-
apoptotic Bcl-2 family members. 
Consequently, the inhibition of Bax and/or 
Bak is relieved, leading to their 
oligomerization and formation of a channel 
through which cytochrome c (cyt-c) is 
released into the cytosol. Then, cyt c 
associates with Apaf-1 and ATP, forming a 
platform for recruitment and activation of 
procaspase-9, also known as the 
apoptosome. Active caspase-9 cleaves 
and activates the downstream executioner 
caspase-3, -6, and -7, which are crucial for 
the execution of apoptotic cell death. In 
addition, other pro-apoptotic proteins 
released from the mitochondria contribute 
to the cellular suicide mechanism (3). 
 
Extrinsic pathway 
The extrinsic pathway of apoptosis is 
induced upon stimulation of death 
receptors belonging to the TNFR family, 
such as TNFR, Fas and TRAIL-R. 
Signalling by these receptors can induce a 
variety of cellular responses, including 
proliferation, differentiation and cell death. 
Apoptosis is induced by the formation of a 
death-inducing signaling complex (DISC). 
In this complex, Fas-associated death 
domain (FADD) recruits the initiator 
caspase-8 and/or -10 via homotypic death 
domain interaction. In contrast to signaling 
induced by Fas and TRAIL-R, TNFR1 
aggregation leads to the sequential 
formation of two complex. Complex 1 
consists of TNFR1, TNFR-associated 
death domain (TRADD). TRAF2, RIP1, 
cIAP1 and cIAP2 and is formed at the 
plasma membrane. These proteins are 
important mediators of TNF-induced 
activation of NF-κB     M PK   
Endocytosis of TNFR1 is followed by the 
formation of complex II, which is 
analogous to the receptor-proximal DISC 
induced by FasL and  TRAIL and includes 
TRADD, FADD, and caspase-8 and/or -10. 
Activation of caspase-8 and -10 leads to 
activation of the downstream executioner  
caspases (3). 
Caspase are the central component of 
the apoptotic response. 
Caspases, being the key effector 
molecules in apoptosis, are potential 
targets for pharmacological modulation of 
cell death (5).  
Caspases (which are so-named as 
they are cysteine proteases that cleave 
after an aspartate residu in their 
substrates) are a conserved family of 
enzymes that irreversibly commit a cell to 
die. Although the first caspase; interleukin- 
 β- converting enzyme (ICE; also known 
as caspase-1), was identified in humans. 
Caspases and their homologues have 
been reported in species that range from 
the nematode to the dipteran Drosophila 
melanogaster and the lepidopteran 
Spodoptera frungiperda, and even the 
yeast Saccharomyces cerevisiae (9). 
Caspases are zymogens (inactive 
enzyme precursors, which require a 
biochemical change to become an active 
enzyme) that consist of an N-terminal 
prodomain followed by a large subunit of 
about 20 kDa, p20, and small subunit of 
about 10 kDa, p10. In a number of 
procaspases, the p20 and p10 subunits 
are separated by a small linker sequence. 
Depending on the structure of the 
prodomain and their function, caspases 
are typically divided into 3 major groups. 
The caspases with large prodomains are 
referred to as inflammatory caspases 
(group I) and initiator of apoptosis 
caspases (group II), while caspases with a 
short prodomain of 20-30 amino acids are 
named effectoe caspases (group III) (9). 
Once activated, initiator caspases 
are responsible for cleaving and activating 
effector  pro-caspases. Effector caspases, 
in turn, cleave various proteins leading to 
morphological and biochemical features  
characteristic of apoptosis (10). 
Caspase inhibition 
In mammals, inhibition of caspase 
is assiciated with the proteins belonging to 
IAPs (inhibitors of apoptosis) family (e.g. 
cIAP-1, cIAP-2, ILP-2, survivin, XIAP, 
Livin, BIRC, NAIP) that are differentiated 
by the presence of three baculoviral IAP 
repeats (BIR) and in some, a RING-finger 
motif at the C-terminus. The IAPs family 
proteins inhibit the function of some 
initiator (e.g. casp-9) and effector 
caspases (casp-3, and 7) by different 
processes, although several several 
initiator as well as effector caspases are 
resistant to inhibition by XIAP.c-IAP1, dan 
cIAP2. The action of caspase-8 has been 
found to be regulated by a family of  
proteins known as FADD-like ICE (FLICE)-
inhibitory proteins (FLIPs). It has been 
found that FLICE-inhibitory proteins 
(FLIPs) derived from a virus (v-FLIPs) are 
capable to bind with FADD and casp-
8 by homotypic interactions and block the 
recruitment of casp-8 to the DISC leading to 
casp-8 inactivation. Regulation of caspase-9 
activity can also be achieved by the release 
of mithocondrial proteins Smac/DIABLO and 
HtrA2/Omi. Now it has become clear that 
ubiquitin-mediated degradation is implicated 
in the regulation of IAPs and proteins with 
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